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Objective: To develop core outcome sets (COS) for studies evaluating interventions for  (1) prevention 45 
and (2) treatment of PPH, and recommendations on how to report the COS. 46 
Design: A two-round Delphi survey and face-to-face meeting. 47 
Population: Health care professionals and women’s representatives. 48 
Methods: Outcomes were identified from systematic reviews of PPH studies and stakeholder 49 
consultation. Participants scored each outcome in the Delphi on a Likert scale between 1 (not important) 50 
and 9 (critically important). Results were discussed at the face-to-face meeting to agree the final COS. 51 
Consensus at the meeting was defined as ≥ 70% of participants scoring the outcome as critically 52 
important (7-9). Lectures, discussion and voting were used to agree how to report COS outcomes.  53 
Main outcome measures: outcomes from systematic reviews and consultations. 54 
 55 
Results: Both Delphi rounds were completed by 152/205 (74%) participants for prevention and 143/197 56 
(73%) for treatment. For prevention of PPH, nine core outcomes were selected: blood loss, shock, 57 
maternal death, use of additional uterotonics, blood transfusion, transfer for higher level of care, women’s 58 
sense of wellbeing, acceptability and satisfaction with the intervention, breastfeeding and adverse effects. 59 
For treatment of PPH, 12 core outcomes were selected: blood loss, shock, coagulopathy, hysterectomy, 60 
organ dysfunction, maternal death, blood transfusion, use of additional haemostatic intervention, transfer 61 
for higher level of care, women’s sense of wellbeing, acceptability and satisfaction with the intervention, 62 
breastfeeding and adverse effects. Recommendations were developed on how to report these outcomes 63 
where possible.   64 
 65 
Conclusions: These COS will help standardise outcome reporting in PPH trials.  66 
 67 
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Over 250,000 women die each year from complications of childbirth.1 PPH is the leading cause of 77 
maternal mortality worldwide.2 It is usually defined as blood loss of 500 ml or more from the genital tract 78 
within 24 hours after childbirth.  79 
 80 
Interventions for PPH have been evaluated in a large number of studies. However evidence is difficult to 81 
interpret and compare across studies due to variations in the outcomes measured by researchers. In a 82 
study looking at outcomes reported in PPH trials published between 1997 and 2015, 121 trials for 83 
prevention of PPH used 68 different primary outcomes.3 The most commonly reported outcome was 84 
assessment of blood loss, with more than ten different cut-offs specified at times ranging from 30 minutes 85 
to 48 hours. There were little data on short and long-term morbidity or mortality, and few patient reported 86 
outcomes.  87 
 88 
Reduction in maternal mortality is part of the Sustainable Development Goals set by the United Nations.1 89 
One strategy for achieving this is to ensure that the most effective evidence based therapies are used to 90 
manage PPH, and global standards follow evidence based guidelines.1 Recommendations can only be 91 
robust if they are based on good quality evidence, where interventions are compared using indicators that 92 
are standardized and are important measures of wellbeing.  93 
 94 
The aim of this project was to develop consensus among international stakeholders on a set of core 95 
outcomes that should be used in trials and systematic reviews to evaluate (1) preventative interventions 96 
and (2) therapeutic interventions for women with PPH. A secondary aim was to provide guidance on how 97 
to report these core outcomes. 98 
  99 
METHODS 100 
 101 
The project was registered prospectively with the Core Outcome Measures in Effectiveness Trials 102 
(COMET) initiative4 and funded by the British Medical Association (BMA). The protocol was peer-103 
reviewed by the COMET team and funding body. Ethics approval was not required.5 The manuscript has 104 
been reported in line with the COS-STAR guidelines for COS reporting.6 Methods are summarised in 105 
Figure S1 and further details are available in Appendix S1. 106 
 107 
The Steering Committee included two obstetricians (SM, ZA), a midwife (AC) and two 108 
methodologists/statisticians with expertise in development of COS (JK, PW). A Scientific Advisory 109 
Group (SAG), set up to provide multidisciplinary expert input and an international perspective, consisted 110 
of 16 members from 10 different countries (Appendix S1). Seven stakeholder groups were agreed a 111 
priori to be relevant to the project (obstetricians, midwives, anaesthetists, haematologists, neonatologists, 112 
health strategists/methodologists and women’s representatives).  113 
 114 
 4 
1. Identification of participants for the Delphi Survey 115 
Our aim was to involve as many participants as possible, with a minimum of 10 in each stakeholder 116 
group to allow numbers to be meaningful taking into account possible attrition in Round 2.8 The same 117 
participants were asked to take both the prevention and treatment PPH surveys. Participants were 118 
identified from published trial reports and Cochrane reviews on PPH. Invitations were also sent through 119 
the CoRe Outcomes in Women’s and Newborn health (CROWN) Initiative journal editors mailing list.9 120 
Women’s representatives were invited through the National Childbirth Trust parent support group (UK) 121 
and personal contacts. Further invitations to stakeholders were sent out by snowballing with suggestions 122 
from the SAG, authors contacted and targeted participants. The SAG also took a modified Delphi survey 123 
separately. This was a methodological investigation to assess the impact of group size on selection of 124 
outcomes for a COS, and will be the subject of a separate paper.  125 
 126 
2. Identification of outcomes 127 
To identify outcomes relevant to PPH, two systematic reviews of randomized trials were undertaken - 128 
one evaluating interventions for prevention of PPH (NA and ZA), the other, treatment of PPH (SM and 129 
ZA) (details in Appendix S1). All published outcomes were considered for inclusion in the COS. .  130 
The reviews identified 121 randomised trials with 160 different outcomes for prevention of PPH and 16 131 
RCTs with 95 different outcomes for treatment of PPH. Outcomes were classified under overarching 132 
domains (blood loss assessment, mortality and morbidity, use of additional interventions and resources, 133 
women’s and clinicians’ views, adverse outcomes, and neonatal outcomes). Duplicate outcomes were 134 
removed, similar outcomes combined and variations in methods of reporting each outcome noted (Tables 135 
S1 and S2). Two outcomes - women’s and healthcare professionals’ views, were added by the Steering 136 
Committee. A total of 35 outcomes for prevention of PPH and 31 outcomes for treatment of PPH were 137 
entered into Round 1 of the Delphi.  138 
 139 
3. Delphi Survey 140 
A two-round, anonymised electronic Delphi survey was designed on DelphiManager10 to obtain 141 
consensus on the importance of each outcome among stakeholders. It was decided a priori that results of 142 
the Delphi would be used to inform the face-to-face stakeholder meeting where a final COS would be 143 
agreed.  144 
 145 
Each outcome was listed in the survey with its plain language summary.  Participants were asked to rate 146 
the importance of each outcome between 1 and 9 on a Likert scale, with 1-3 being ‘not important’, 3-6 147 
‘important but not critical’ and 7-9 being ‘critically important’ to report in trials, or select unable to 148 
comment. This scale is recommended by the Grading of Recommendations Assessment, Development 149 
and Evaluation working group.12 Participants were invited to suggest additional outcomes for 150 
consideration for the COS in Round 1 using free-text responses.  151 
 152 
 5 
Potential participants were invited to register for the study via email, and the Delphi survey was emailed 153 
to those who registered. The closing date was set 4 weeks after each round and an e-mail reminder was 154 
sent on days 14, 21, and 28. Non-responders in Round 1 were not invited to participate in Round 2. Non-155 
responders in Round 2 were sent additional emails to improve response rate. 156 
 157 
In Round 2, participants were able to view anonymised results from the first round, presented as the 158 
distribution of scores for each outcome in each stakeholder group separately. This allowed participants to 159 
reflect on their choices prior to completing the second round of the survey. Additional relevent outcomes 160 
suggested by participants in Round 1 were were added to Round 2 (16 for prevention and 18 for 161 
treatment) (Figures S2 and S3).  162 
 163 
We defined consensus for the Delphi a priori based on guidance in The COMET Handbook.8 For 164 
inclusion in the COS, outcomes required at least 70% of participants in each stakeholder group to score 165 
the outcome as critically important and less than 15% to score the outcome as not important. Outcomes 166 
excluded from the COS required at least 70% of participants in each stakeholder group to score the 167 
outcome as not important and less than 15% to score the outcome as “critical.”  If outcomes did not meet 168 
either criterion they were classified as outcomes with no consensus. 169 
 170 
4. Face-to-face meeting 171 
The final phase of the project was a face-to-face consensus meeting (Liverpool, United Kingdom 16-17th 172 
August 2016). Twenty-five people attended the meeting, and each stakeholder group was represented: 173 
five obstetricians, three midwives, four women’s representatives, five health strategist/methodologists, 174 
one anaesthetist, one haematologist, and one neonatologist (Appendix S1). Findings of the survey were 175 
presented and participants were given an opportunity to discuss each outcome. Consideration was given 176 
as to whether the outcome was relevant in all setting and for all women recruited. Outcomes could be re-177 
named or reconfigured if there was full consensus at the meeting to do so. Participants then scored each 178 
outcome between 1 and 9 on the Likert scale, for inclusion or exclusion in the COS with an anonymous 179 
voting system using electronic keypads. Consensus at the meeting required a majority of 70% of 180 
participants to score the outcome as critically important (7-9) to include in the COS.  181 
 182 
5. Methodology for how to report outcomes 183 
Consensus on how to report the COS outcomes was developed on Day 2 of the meeting by an Expert 184 
Committee (n=20; Appendix S1). The aim was not to create new definitions but to select a preferred 185 
method of reporting the outcome among existing methods in published literature where possible and to 186 
make research recommendations where this was not possible.  187 
 188 
We used recommended standards on how to report summary results for trial reporting13  and considered 189 
the specific metric on how to measure the outcome, the method of data aggregation (continuous or 190 
categorical) and the time frame in which to measure the outcome.. Variations in outcome reporting were 191 
presented and expert presentations delivered. Options were discussed, and scored. Consensus was defined 192 
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a priori as more than 70% of participants voting for a preferred option of reporting, and majority view 193 
was defined as more than 50% of participants preferring one option from among the top three options, 194 




Survey participants came from 36 different countries (Figure S4), and represented all seven stakeholder 199 
groups. For Round 1 of the Delphi, 205 participants responded to the prevention of PPH survey and 197 200 
to the treatment survey. Round 2 was completed by 74% (152/205) and 73% (143/197) of participants 201 
respectively (Table 1).   Overall, 77% of those who took the survey had exposure to PPH either through 202 
personal experience or through caring for women who had experienced PPH. Among women’s 203 
representatives, 41% had experienced a PPH. 204 
 205 
Assessment of outcomes for the prevention and treatment of PPH COS is shown in Figure 1.  Delphi 206 
consensus was reached for including five outcomes in the COS for prevention of PPH and ten outcomes 207 
in the COS for treatment of PPH. No outcomes fulfilled criteria for exclusion. There was no consensus on 208 
the remaining outcomes. These results were discussed at the face-to face meeting and the final COS 209 
agreed included nine outcomes for the prevention COS and 12 outcomes for the treatment COS (Tables 2 210 
and 3). At least one outcome was included from each domain for both prevention and treatment COS, and 211 
there was significant overlap in outcomes included in the two COS. 212 
 213 
1. PPH Prevention COS 214 
For the evaluation of interventions for prevention of PPH, the final COS outcomes are presented in Table 215 
2. At the stakeholder meeting, all outcomes included in the Delphi consensus were included in the COS 216 
except for hysterectomy. Although stakeholders at the meeting agreed that hysterectomy was an 217 
important outcome, it was not felt to be a critically important outcome in the context of trials for 218 
prevention of PPH because it is a very rare event. Although rare but critically important outcomes are 219 
also important to include in a COS, and such an outcome of maternal mortality has been included in the 220 
prevention of PPH COS, there was consensus that the PPH prevention COS would be more informative if 221 
it captured other measures of maternal morbidity for which data were more likely to be available from 222 
trials rather than having a COS with little data available for multiple outcomes. Four additional outcomes 223 
were included in the PPH prevention COS subsequent to stakeholder discussions and voting. Two of 224 
these outcomes, ‘use of blood transfusion’ and ‘use of additional uterotonics’ were borderline for 225 
inclusion in the Delphi survey (Table 2). The outcomes ‘transfer to ITU’ and ‘transfer to a higher 226 
facility’ in the Delphi were reconfigured at the stakeholder meeting to ‘transfer to a higher level of care’ 227 
to capture data on an escalation in the level of care required for the woman, which, it was recognized, 228 
would depend on the initial setting of the woman. There was also consensus among stakeholders at the 229 
meeting that patient reported outcomes, although not included in the Delphi consensus, were important to 230 
include in the COS, and this was strongly advocated by the women’s representatives. It was felt that these 231 
should capture a woman’s sense of wellbeing, as well as acceptability and satisfaction with the 232 
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intervention. Among outcomes in the neonatal domain, there was consensus that breastfeeding would be 233 
an important outcome as a PPH may impact on a woman’s wellness and ability to establish or maintain 234 
breastfeeding if she intended to breastfeed, or there could be a potential impact of the intervention on 235 
breast milk itself. 236 
 237 
2. PPH Treatment COS 238 
For the evaluation of interventions for treatment of PPH, the final COS are presented in Table 3. At the 239 
stakeholder meeting, nine of the 10 outcomes included in the Delphi were included in the final COS.. The 240 
outcomes ‘shock’ and ‘maternal resuscitation due to shock’ were both included by the Delphi survey. 241 
However, as both outcomes were very similar, consensus at the meeting was to include ‘shock’ only in 242 
preference to ‘maternal resuscitation due to shock’ as the latter would be more complex to measure or 243 
assess. The outcome disseminated intravascular coagulation, (DIC) was renamed as coagulopathy based 244 
on recommendations by haematologists because coagulopathy is the more accurate term; DIC does not 245 
have a validated definition in PPH and constitutes only a small subset of coagulopathies associated with 246 
PPH. Multiple organ failure was renamed as ‘any organ dysfunction’, in line with the World Health 247 
Organization’s recommendations on how to capture severe pregnancy complications including organ 248 
dysfunction in the WHO near-miss approach for maternal health.14 A number of outcomes in the Delphi 249 
survey aimed at capturing failure of initial treatment, such as use of additional medical or advanced 250 
surgical interventions such as balloon insertion or uterine artery embolisation or ligation. However, at the 251 
meeting it was recognized that type of escalation of therapy would depend on the trial intervention itself – 252 
medical or surgical. Therefore, these outcomes were reconfigured into the outcome ‘Use of any 253 
additional haemostatic intervention’ to capture failure of the trial intervention itself, as this would be 254 
applicable to all trials, regardless of the intervention they were evaluating.  The other outcomes added 255 
were a woman’s sense of wellbeing and acceptability and satisfaction with the intervention and 256 
breastfeeding as specified above in the prevention of PPH COS.  257 
 258 
3. How to report COS outcomes 259 
The Expert Committee Recommendations on how to report the COS outcomes are presented in Table 4, 260 
along with explanations.  Most recommendations were agreed by consensus. Those agreed by a majority 261 
view included reporting of hysterectomies specifically carried out to stop PPH, to avoid confounding data 262 
with hysterectomies carried out prophylactically or for other indications. For time frames for measuring 263 
outcomes, there was consensus that in the context of randomised trials outcome data should be collected 264 
from the point of randomisation. The time limit up to which outcomes should be measured was left to 265 
trialists for most outcomes to accommodate for local protocols and resource availability. However a 266 
majority view recommendation was put forward for blood loss to be assessed (measured or estimated) up 267 
to cessation of active bleeding, as this is an area where standardization is particularly lacking and time 268 
frame selection is likely to impact on data significantly. For hysterectomy, the majority recommendation 269 
was to report it at least up to hospital discharge as most hysterectomies are likely to occur by that time in 270 
the context of PPH. 271 
 272 
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For the patient reported outcomes and breastfeeding, it was felt by the stakeholder groups that further 273 
work was needed to develop tools to capture what aspects of these outcomes were most important to 274 




Main findings 279 
Consensus on PPH COS was developed among an international panel of stakeholders through a Delphi 280 
survey and face-to-face meeting. For the evaluation of interventions for prevention of PPH, nine core 281 
outcomes were selected and for treatment of PPH, 12 core outcomes. Expert committee recommendations 282 
where developed on how to report each outcome where possible, and a research agenda was set for two 283 
outcomes where this was not possible.  284 
  285 
Strengths and Limitations 286 
This project has several strengths.  Firstly, the methodology was defined a priori based on guidelines by 287 
the COMET Initiative.8 The Delphi exercise has the advantage of including views of a larger number of 288 
geographically distant participants. Participants in the Delphi were still able to consider the views of 289 
other stakeholder groups in Round 2, to reconsider their opinion without being overly influenced by 290 
domineering individuals. Results were further refined at the face-to-face meeting which allowed for rich 291 
discussions as well as the ability to debate and persuade others. Secondly, stakeholders came from a 292 
range of relevant specialties. Importantly, consumer representatives, who are sometimes overlooked in 293 
similar projects,25-26 were included at all stages of the process. There was representation from both those 294 
who had and had not experienced PPH. Our parent representatives impacted the final COS outcomes by 295 
influencing other stakeholders at the face-to-face meeting to include patient reported outcomes. Thirdly, 296 
there was representation from a wide range of countries (high, middle and low income) in the Delphi and 297 
at the face-to-face meeting, so that the COS developed would be applicable across different settings. 298 
Fourthly, we have developed COS for both prevention and treatment of PPH to cover the full spectrum of 299 
PPH intervention trials. It is not surprising that there is significant overlap in outcomes selected for the 300 
two COS. However the PPH treatment COS appropriately includes more outcomes that would capture 301 
significant maternal morbidity in the presence of an established PPH. And finally, a COS often tells 302 
researchers what outcomes to use, but not how to report them, making it difficult to achieve adequate 303 
standardisation; we have developed Expert Committee Recommendations on how to report the outcomes 304 
selected for PPH COS to provide better guidance to researchers.  305 
 306 
The limitations of this project are that outcomes were obtained largely from systematic reviews and 307 
participants in the Delphi exercise; we did not conduct formal interviews with women. Secondly, we 308 
asked participants to identify one key stakeholder group to which they belonged. Some participants may 309 
have belonged to more than one stakeholder group and this may have influenced how they scored 310 
outcomes, but data are not available to explore this further. Thirdly, representation from each stakeholder 311 
groups was not equal; this may have impacted on the outcomes selected. Finally, although we have 312 
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developed guidance on how to report COS outcomes, these recommendations are from a small group of 313 
experts, and have not been subjected to the same rigorous Delphi process in a large group. However, it is 314 
debatable whether a Delphi process is the optimum method for developing consensus on how to report 315 
outcomes. More complex discussions may need to be undertaken for consensus on measurement 316 
instruments by stakeholders who may be different from those partaking in the ‘what to measure’ Delphi. 317 
Generic methodological guidelines on how to select standardised instrument measures for outcomes have 318 
recently been published.27 They recommend identifying all possible measurement instruments for an 319 
outcome, and selecting one with high quality of evidence for good validity and internal consistency, that 320 
is feasible to measure in the target population. These guidelines have not yet been applied prospectively 321 
for COS in maternal health. Our systematic reviews identified the different ways in which COS outcomes 322 
have been reported, and the feasibility of applying the instruments in an international setting was 323 
considered when making recommendations on how to report outcomes. While validity may be excellent 324 
for the more objective outcomes included in the COS, such as units of blood transfusion or maternal 325 
death, measurement tools for other outcomes such as blood loss are well known for their poor accuracy.   326 
 327 
Interpretation 328 
To our knowledge, there are no other published COS for PPH. These COS include outcomes that capture 329 
meaningful morbidity (shock, hysterectomy, organ dysfunction) and mortality. They also include 330 
outcomes with high event rates upon which sample size calculations could be based for smaller studies 331 
(blood loss, use of additional uterotonics or blood transfusion).  Resource use may be assessed through 332 
use of additional interventions and level of care such as ITU use. Patient reported outcomes (woman’s 333 
sense of wellbeing, acceptability/satisfaction with the intervention) and breastfeeding are also captured 334 
but require further qualitative research on how best to measure these outcomes. Until further data are 335 
available, we would encourage researchers to clearly report the measures they have used. 336 
 337 
Although these outcomes aim to assess the impact of interventions evaluated on severity of PPH, some 338 
outcomes may be influenced by local practices. For example, thresholds used for transfusing blood or 339 
transferring a woman for higher level of care may vary across trial settings and studies. For such 340 
outcomes we would encourage authors to interpret results bearing the potential impact of local practices 341 
in mind. 342 
 343 
We would recommend researchers evaluating interventions for PPH to report these COS outcomes as a 344 
minimum, along with any other outcomes of interest to their study. Where these COS are not reported, 345 
researchers are encouraged to provide an explanation, for transparency and to reduce the risk of reporting 346 
bias. Future trials evaluating interventions for PPH should report any barriers identified to data collection 347 
for these COS outcomes. COS may be updated to provide guidance in response to such feedback.  348 
 349 
CONCLUSIONS 350 
The PPH COS, developed through an international multidisciplinary effort, will help standardise outcome 351 
reporting in this area, and facilitate comparison of data across studies, to guide clinical practice. We 352 
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recommend that researchers evaluating interventions for PPH prevention and treatment should report 353 
these COS outcomes as a minimum, along with any other outcomes of interest. Further work is needed on 354 
how to best to report women’s sense of wellbeing, acceptability and satisfaction with the intervention and 355 
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